Build the Immune Infrastructure for Oncology
We are building a company around one conviction:
we can reprogram the immune system to combat solid tumors.
Novastra builds XIRT™ on its OmniAntigen™ Platform, a first-in-class category of immune therapy designed to rebuild the tumor-specific immune responses that checkpoint and combination therapies depend on but cannot create on their own.
Why Novastra
Shape a First-in-Class Platform
Advance XIRT™ across clinical, pediatric, and in situ programs, each built on one core platform.
Science Already in the Clinic
Join a platform grounded in a decade of peer-reviewed research and now in human clinical evaluation.
Own Outcomes That Reach Patients
At our scale, every role carries real ownership and a direct line to the programs that reach patients.
How We Work
Scientific rigor over hype. Agility with accountability.
Patients at the center.
We follow the evidence, communicate what the data can and cannot support, and move with the discipline to translate complex science into regulated therapies.
Opportunities
Novastra is expanding across:
Clinical Development
Regulatory Affairs
Chemistry, Manufacturing and Controls (CMC)
Specific openings will be posted as programs advance through IND-enabling activities.
We also welcome introductions from exceptional scientists, engineers, clinicians, and regulatory leaders who share our mission. Email careers@novastra.bio.